Synthesis and target identification of hymenialdisine analogs

Chemistry and Biology

Volumn 11, Issue 2, 2004, Pages 247-259

  Wan, Yongqin ^a   Hur, Wooyoung ^a   Cho, Charles Y ^b   Liu, Yi ^a   Adrian, Francisco J ^a   Lozach, Olivier ^c   Bach, Stéphane ^c   Mayer, Thomas ^d   Fabbro, Doriano ^d   Meijer, Laurent ^c   Gray, Nathanael S ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c STATION BIOLOGIQUE   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1542381392     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.01.015     Document Type: Article

References (75)

1. Sridhar R., Hanson-Painton O., Cooper D.R. Protein kinase as therapeutic targets. Pharm. Res. 17:2000;1345-1353.
2. García-Echeverría C., Traxler P., Evans D.B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 20:2000;28-57.
3. Sielecki T.M., Boylan J.F., Benfield P.A., Trainor G.L. Cyclin-dependent kinase inhibitors. useful targets in cell cycle regulation J. Med. Chem. 43:2000;1-18.
4. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., O'Reilly T., Wood J., Zimmermann J. Tyrosine kinase inhibitors. from rational design to clinical trials Med. Res. Rev. 21:2001;499-512.
5. Toogood P.L. Cyclin-dependent kinase inhibitors for treating cancer. Med. Res. Rev. 21:2001;487-498.
6. Bridges A.J. Chemical inhibitors of protein kinases. Chem. Rev. 101:2001;2541-2572.
7. Scapin G. Structural biology in drug design. selective protein kinase inhibitors Drug Discov. Today. 7:2001;601-611.
8. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Gene Dev. 9:1999;104-111.
9. Malumbres M., Barbacid M. Milestones in cell division. to cycle or not to cycle: a critical decision in cancer Nat. Rev. Cancer. 1:2001;222-231.
10. Ali A., Hoeflich K.P., Woodgett J.R. Glycogen synthase kinase-3. properties, functions, and regulation Chem. Rev. 101:2001;2527-2540.
11. Imahori K., Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. (Tokyo). 121:1997;179-188.
12. Mandelkow E.-M., Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 8:1998;425-427.
13. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22:2002;373-384.
14. Profit A.A., Lee T.R., Lawrence D.S. Bivalent inhibitors of protein tyrosine kinases. J. Am. Chem. Soc. 121:1999;280-283.
15. Martinez A., Alonso M., Castro A., Pérez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3 (GSK-3) inhibitors. thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 45:2002;1292-1299.
16. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
17. Rewcastle G.W., Murray D.K., Elliott W.L., Fry D.W., Howard C.T., Nelson J.M., Roberts B.J., Vincent P.W., Showalter H.D., Winters R.T.et al. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino- substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4- d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 41:1998;742-751.
18. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors. 4-(phenylamino)pyrazolo[3,4-d]pyrimidines J. Med. Chem. 40:1997;3601-3616.
19. Traxler P.M., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. 4-(Phenylamino)pyrrolopyrimidines. potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 39:1996;2285-2292.
20. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the ABL-kinase. phenylaminopyrimidine (PAP) derivatives Bioorg. Med. Chem. Lett. 7:1997;187-192.
21. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W.et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
22. Sun L., Tran F., App H., Hirth P., McMahon G., Tang C. Synthesis and biological evaluations of 3-substituted indolin-2-ones. a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases J. Med. Chem. 41:1998;2588-2603.
23. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J.Y., Detivaud L., Leclerc S.et al. Inhibition of cyclin-dependent kinases by purine analogs. Eur. J. Biochem. 224:1994;771-786.
24. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.H. Inhibition of cyclin-dependent kinases by purine analogs. Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:1997;518-526.
25. Gray N.S., Wodicka L., Thunnissen A.-M.W.H., Normann T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L.et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
26. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:2002;417-425.
27. Chang Y.T., Gray N.S., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 5:1996;361-375.
28. Legraverend M., Tunnah P., Noble M., Ducrot P., Ludwig O., Grierson D.S., Leost M., Meijer L., Endicott J. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43:2000;1282-1292.
29. Lee J.C., Badger A.M., Griswold D.E., Dunnington D., Truneh A., Votta B., White J.R., Young P.R., Bender P.E. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. N Y Acad. Sci. 696:1993;149-170.
30. Adams J.L., Boehm J.C., Kassis S., Gorycki P.D., Webb E.F., Hall R., Sorenson M., Lee J.C., Ayrton A., Grisword D.E.et al. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 8:1998;3111-3116.
31. Laufer S.A., Wagner G.K., Kotschenreuther D.A., Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 46:2003;3230-3244.
32. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
33. Losiewicz M.D., Carlson B.A., Kaur G., Sausville E.A., Worland P.J. Potent inhibition of Cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:1994;589-595.
34. Zaharevitz D.W., Gussio R., Leost M., Senderowicz A.M., Lahusen T., Kunick C., Meijer L., Sausville E.A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59:1999;2566-2569.
35. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., Meijer L., Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors. synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity J. Med. Chem. 42:1999;2909-2919.
36. Leost M., Schultz C., Link A., Wu Y.-Z., Biernat J., Mandelkow E.-M., Bibb J.A., Snyder G.L., Greengard P., Zaharevitz D.W.et al. Paullones are potent inhibitors of glycogen synthase kinase-3b and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267:2000;5983-5994.
37. Furusaki A., Hashiba N., Matsumoto T., Hirano A., Iwai Y., Omurs S. The crystal and molecular structure of staurosporine, a new alkaloid from a Streptomyces strain. Bull. Chem. Soc. Jpn. 55:1982;3681-3685.
38. Gadbois D.M., Hamaguchi J.R., Swank R.A., Bradbury E.M. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun. 184:1992;80-85.
39. Hudkins R.L., Iqbal M., Park C.-H., Goldstein J., Herman J., Shek E., Murakata C., Mallamo J.P. Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorg. Med. Chem. Lett. 8:1998;1873-1876.
40. Cimino G., De Rosa S., De Stefano S., Mazzarella L., Puliti R., Sodano G. Isolation and x-ray crystal structure of a novel bromo compound from two marine sponges. Tetrahedron Lett. 23:1982;767-768.
41. Kitagawa I., Kobayashi M., Kitanaka K., Kido M., Kyogoku Y. Marine natural products. XII. On the chemical constituents of the Okinawan marine sponge Hymeniacidon aldis. Chem. Pharm. Bull. 31:1983;2321-2328.
42. De Nanteuil G., Ahond A., Guilhem J., Poupat C., Tran Huu Dau E., Potier P., Pusset M., Pusset J., Laboute P. Marine invertebrates from the New Caledonian lagoon. V. Isolation and identification of metabolites of a new species of sponge, Pseudaxinyssa cantharella. Tetrahedron Lett. 41:1985;6019-6033.
43. Schmitz F.J., Gunasekera S.P., Lakshmi V., Tillekeratne L.M.V. Marine natural products. pyrrololactams from several sponges J. Nat. Prod. 48:1985;47-53.
44. Pettit G.R., Herald C.L., Leet J.E., Gupta R., Schaufelberger D.E., Bates R.B., Clewlow P.J., Doubek D.L., Manfredi K.P., Rützler K.et al. Antineoplastic agents. 168. Isolation and structure of axinohydantoin. Can. J. Chem. 68:1990;1621-1624.
45. Meijer L., Thunnissen A.-M.W.H., White A.W., Garnier M., Nikolic M., Tsai L.-H., Walter J., Cleverley K.E., Salinas P.C., Wu Y.-Z.et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7:1999;51-63.
46. Tasdemir D., Mallon R., Greenstein M., Feldberg L.R., Kim S.C., Collins K., Wojciechowicz D., Mangalindan G.C., Concepción G.P., Harper M.K.et al. Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J. Med. Chem. 45:2002;529-532.
47. Curman D., Cinel B., Williams D.E., Rundle N., Block W.D., Goodarzi A.A., Hutchins J.R., Clarke P.R., Zhou B.-B., Lees-Miller S.P.et al. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 276:2001;17914-17919.
48. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 334:1988;661-665.
49. Nishizuka Y. The family of protein kinase C for signal transduction. JAMA. 262:1989;1826-1833.
50. Nambi, P., and Patil, A.D. (September, 1993). Imidazolinylidenepyrroloazepine derivatives as protein kinase C inhibitor. Patent WO-9316703.
51. Breton J.J., Chabot-Fletcher M.C. The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-κB. J. Pharmacol. Exp. Ther. 282:1997;459-466.
52. 2 formation by the marine natural product hymenialdisine. J. Pharmacol. Exp. Ther. 283:1997;955-961.
53. Badger A.M., Cook M.N., Swift B.A., Newman-Tarr T.M., Gowen M., Lark M. Inhibition of interleukin-1-induced proteoglycan degradation and nitric oxide production in bovine articular cartilage/chondrocyte cultures by the natural product, hymenialdisine. J. Pharmacol. Exp. Ther. 290:1999;587-593.
54. Knockaert M., Gray N., Damiens E., Chang Y.-T., Grellier P., Grant K., Fergusson D., Mottram J., Soete M., Dubremetz J.-F.et al. Intracellular targets of cyclin-dependent kinase inhibitors. identification by affinity chromatography using immobilised inhibitors Chem. Biol. 7:2000;411-422.
55. Knockaert M., Wieking K., Schmitt S., Leost M., Grant K.M., Mottram J.C., Kunick C., Meijer L. Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 277:2002;25493-25501.
56. Annoura H., Tatsuoka T. Total syntheses of hymenialdisine and debromohymenialdisine. stereospecific construction of the 2-amino-4-oxo-2- imidazolin-5(Z)-disubstituted ylidene ring system Tetrahedron Lett. 36:1995;413-416.
57. Xu Y.-Z., Yakushijin K., Horne D.A. Synthesis of C11N5 marine sponge alkaloids. (±)-hymenin, stevensine, hymenialdisine, and debromohymenialdisine J. Org. Chem. 62:1997;456-464.
58. Sosa A.C.B., Yakushijin K., Horne D.A. A practical synthesis of (Z)-debromohymenialdisine. J. Org. Chem. 65:2000;610-611.
59. Chacun-Lefévre L., Joseph B., Mérour J.-Y. Synthesis and reactivity of azepino[3,4-b]indol-5-yl trifluoromethanesulfonate. Tetrahedron. 56:2000;4491-4499.
60. Chacun-Lefévre L., Joseph B., Mérour J.-Y. Intramolecular Heck coupling of alkenyl 3-iodoindole-2-carboxamide derivatives. Synlett. 6:2001;848-850.
61. Erdélyl M., Gogoll A. Rapid homogeneous-phase Sonogashira coupling reactions using controlled microwave heating. J. Org. Chem. 66:2001;4165-4169.
62. Kearns A.E., Donohue M.M., Sanyal B., Demay M.B. Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro. J. Biol. Chem. 276:2001;42213-42218.
63. Primot A., Baratte B., Gompel M., Borgne A., Liabeuf S., Romette J.-L., Jho E.-h., Costantini F., Meijer L. Purification of GSK-3 by affinity chromatography on immobilized axin. Protein Expr. Purif. 20:2000;394-404.
64. Davis S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 251:2000;95-105.
65. Bain J., McLauchan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors. an update Biochem. J. 371:2003;199-204.
66. Cho H., Matsuki S. Ring construction of several heterocycles with phosphorus pentoxide-methanesulfonic acid (PPMA). Heterocycles. 43:1996;127-131.
67. Kano S., Yokomatsu T., Nemoto H., Shibuya S. An efficient diastereoselective synthesis of 6-hydroxy-4a-[3,4-crowned(15-crown-5)phenyl]- trans-decahydroisoquinoline. Tetrahedron Lett. 26:1985;1531-1534.
68. Kano S., Yokomatsu T., Nemoto H., Shibuya S. Effect of A-strain on a diastereoselective synthesis of 6-hydroxy-4a-aryldecahydroisoquinolines; revised structures of N-acyliminium ion-polyene cyclization products. J. Org. Chem. 51:1986;561-564.
69. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:1997;727-748.
70. Tarricone C., Dhavan R., Peng J., Areces L.B., Tsai L.H., Musacchio A. Structure and regulation of the CDK5-p25 (nck5a) complex. Mol. Cell. 8:2001;657-669.
71. Davies T.G., Tunnah P., Meijer L., Marko D., Eisenbrand G., Endicott J.A., Noble M.E. Inhibitor binding to active and inactive CDK2. the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate Structure. 9:2001;389-397.
72. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68:1996;850-858.
73. Kussmann M., Nordhoff E., Rahbek-Nielsen H., Haebel S., Rossel-Larsen M., Jakobsen L., Gobom J., Mirgorodskaya E., Kroll-Kristensen A., Palm L.et al. Matrix-assisted laser desorption/ionization mass spectrometry sample preparation techniques designed for various peptide and protein analytes. J. Mass Spectrom. 32:1997;593-601.
74. Zhang W., Chait B.T. ProFound. an expert system for protein identification using mass spectrometric peptide mapping information Anal. Chem. 72:2000;2482-2489.
75. Cook N.D. Scintillation proximity assay - a versatile high throughput screening technology. Drug Discov. Today. 1:1996;287-294.